Enric Llorens (@Ellorebo) header
Enric Llorens (@Ellorebo) profile picture

Group Leader and Assistant Professor at Karolinska Institutet. Applying genomics tools to study nervous system regeneration. Interested in…see below

Stockholm, Sweden
Joined December 2014
Photo by Enric Llorens (@Ellorebo)Photo by Enric Llorens (@Ellorebo)Photo by Enric Llorens (@Ellorebo)Photo by Enric Llorens (@Ellorebo)Photo by Enric Llorens (@Ellorebo)Photo by Enric Llorens (@Ellorebo)Photo by Enric Llorens (@Ellorebo)Photo by Enric Llorens (@Ellorebo)Photo by Enric Llorens (@Ellorebo)Photo by Enric Llorens (@Ellorebo)
Enric Llorens retweeted
Erdinc Sezgin @Sciezgin was not in the aging field when he came to us with an idea: test whether membrane fluidity, stiffness, viscosity and molecular organization could be measured together to build a biophysical clock of aging and resilience. We funded him to pursue it via @impetusgrants. He has since produced three papers building what he needs to answer that question, including better probes for labelling cell membranes, software that turns images into biophysical measurements, and evidence that membrane properties distinguish cell states. The longevity field is richer with people like Erdinc joining from other fields and bringing new expertise with them. Read the papers here: doi.org/10.1039/d5cb00116a doi.org/10.1242/jcs.262166 doi.org/10.1101/2024.01.15.5…
8
1
24
1,680
Last night, I gave a speech for the University of Washington's "Neuroscience, AI and Society" lecture series, through the university's Computational Neuroscience Center. 1/
3
68
27
149
64,409
Enric Llorens retweeted
A single E. coli weighs about one picogram, or 60 million times less than a grain of sand. How do we know that? For my latest @AsimovPress essay, I explain how scientists weigh cells. In one case, in the 1950s, they did it using little more than sugar water and a microscope.
5
17
2
132
9,298
Join us at the Nobel Symposium Multiple Sclerosis: Past, Present and Future Treatments June 5th, 2025 | Jacob Berzelius lecture hall @karolinskainst| Stockholm, Sweden free registration at: jirango.com/cview/web/f04950…
1
14
1
33
3,799
Enric Llorens retweeted
Delighted to share a step-by-step protocol for spatially resolved epigenome-transcriptome co-sequencing to map tissue development, aging & disease. Fully committed to open science!! ⁦@sennetresearch⁩ ⁦@_hubmap⁩ ⁦@NIH_CommonFund⁩ @NCIHTAN nature.com/articles/s41596-0…
6
47
3
200
15,291
Enric Llorens retweeted
Too many people take biomedical innovation for granted.
204
3,528
260
29,748
1,379,730
I'm Italian. Over the years, it's been painful seeing Europe’s demise: 1960 - EU was 36% of global GDP 2008 - US GDP surpassed EU Today - US economy 50% larger than EU But why such a decline and is there any hope? Here's everything you need to know about the fall of Europe:
1,235
3,727
559
25,691
3,750,609
Enric Llorens retweeted
🇪🇺 eu/acc @EmmanuelMacron is the only European leader who gets the seriousness of the situation right now: The EU has only 2 or 3 years to stave off total US and China dominance Washington and Beijing are leaving the European Union lagging behind, French President Emmanuel Macron said in pessimistic remarks. “Our former model is over. We are overregulating and underinvesting. In the two to three years to come, if we follow our classical agenda, we will be out of the market,” he warned during a panel discussion at the Berlin Global Dialogue meeting on Wednesday. “The EU could die, we are on a verge of a very important moment,” he added. The French president argued that Europe is lagging behind the Unites States and China on key files such as climate change, AI, defense and security. Former European Central Bank President Mario Draghi raised a similar warning in a report published in September, saying that the EU faces an "existential challenge" unless it radically transforms its economy to enhance its competitiveness. Macron said he fully supports Draghi's conclusions and that Europe should rush to implement them. "I think this is quite true, we are at risk," he said. “They invest much more, they are much more in advance,” he said, adding that looking at gross domestic product (GDP) per capita in the past three decades the U.S. delivered an increase of 60 percent, Europe only delivered 30 percent. “And it's not sustainable with the social model that we have,” he added.
307
277
78
3,165
425,384
We had an amazing symposium! Thanks to @SethBlackshaw @naomi_habib @AnnaMolofskyLab @hutson_tom @kathe_claudia, Ariel Levine, Homaira Nawabi and Leonor Saúde for sharing their impressive research and coming to Stockholm. Great fun to have you all here! 🙏@Ellorebo co-organizing.
1
6
26
2,762
Enric Llorens retweeted
2008 Beijing Olympics Opening Ceremony
2,845
35,520
8,820
309,475
78,845,704
Enric Llorens retweeted
Hiring alert 📢 my lab has TWO openings for a postdoc in computational biology! Please apply if you're interested to work with large in situ RNA-seq datasets and amazed by developing biological neural networks (mouse brains): ki.varbi.com/en/what:job/job… ki.varbi.com/en/what:job/job…
1
41
2
68
9,417
#PosidoniaOceanica: Not algae, but vital plant🌿 supporting thousands of marine species🐟🦀. 2️⃣million hectares in the Mediterranean, millions of years old. Crucial for nature & humans, yet misunderstood and threatened. Protect this important ecosystem👉 bit.ly/4bM1iaG
13
2
32
1,803
It's been 60 years since Epstein-Barr virus (EBV) was discovered. Still, still scientists are continuing to learn fascinating facts about this EBV. A new paper in @Nature by Sylvain Latour and colleagues from INSERM, Paris, report a remarkable human genetics discovery that reveals an important biology of EBV infection--the role of IL27 and its receptor in EBV infection. Martin et al. Nature nature.com/articles/s41586-0… The authors found that individuals who were born with complete deficiency of a cytokine receptor, IL27RA, are highly susceptible to severe EBV infection. But the remarkable part of the discovery is that, despite severe EBV infection, none of these individuals developed cancer; they are protected from EBV-induced cancer risk. If there is one virus that oncologists might know better than virologists, it's EBV. Discovered in 1964 based on microscopy examinations of tumor cells from cancer tissue biopsied from African children, EBV was the first ever known oncogenic virus (thelancet.com/journals/lance…). If you are curious, listen to this 6 mins video where famous scientist/author Dorothy Crawford tells the story of EBV discovery (youtube.com/watch?v=_-Jx4KqC…). EBV infection is extremely common. More than 95% of the population gets it at some point in their life. Once the virus enters the body, it permanently lives dormant in your B cells until you die. In some individuals, such as those immunocompromised, reactivation of this latent infection results in uncontrolled proliferation of B cells causing lymphoma. Not just lymphoma, EBV also cause stomach cancer and nasopharyngeal cancer. Most of the knowledge on the immune pathways hijacked by EBV came to light through humans born with rare genetic mutations causing different types of immunodeficiency. All such known monogenic conditions leading to severe EBV infection almost always have led to cancer. This is the first time scientists are encountering a genetic defect which increases the risk of severe EBV infection but protects against cancer. The finding has perhaps revealed the Achilles' heel of EBV infection, which could be exploited to prevent cancer development in immunocompromised individuals with EBV infection. The other fascinating part of the finding is one of the loss of functions has drifted to higher frequency (0.7%) in Finnish population. So, there are more than 200 individuals in Finland who are knockouts for IL27RA. In the Finngen biobank, the authors found 15 homozygotes, of which two were hospitalized for EBV infection (>50-fold enrichment). The Finnish variant is probably incompletely penetrance because the variant do not completely inactivates IL27R; it leaves behind some residual activity. Just a couple of years ago, Bjornevik et al. demonstrated the strong association of EBV with multiple sclerosis (science.org/doi/10.1126/scie…). Shortly after this report, Lanz et al showed that the reason for 32-fold increased risk of MS after EBV infection is because of the resemblance of a antigen protein in EBV with a glial cell protein in the CNS, resulting in collateral damage in the immune defense against EBV (nature.com/articles/s41586-0…). Currently, mRNA vaccines are being trialed based on this finding. With the recent discovery of IL27 and its receptor IL27RA in EBV, I wonder if these genes have links to MS risk. If so, targeting these genes might also help with treating MS. We will know soon. Amazing discovery. Yet another incredible demonstration of the power of 'natural experiments' aka human genetics in understanding the fundamental biology. Martin et al. Nature nature.com/articles/s41586-0…
2
28
117
18,497
Exciting to see Ionis's UBE3A ASO program for Angelman syndrome is making promising progress, with positive results in the initial phase trials. ir.ionispharma.com/news-rele… There is a fascinating biology behind the therapeutic design here. I've written about it previously (teapaw.org/doctorveera/status/168…). Angelman is one of the well studied imprinting disorder caused by deletions of the only active copy of UBE3A, the maternally derived chromosome. The paternal copy is silenced naturally by a nearby antisense RNA that is expressed only in the paternal chromosome. The discovery of the imprinting mechanism is fascinating, as it involved a touch of serendipity (nature.com/articles/ng0598-1…). Researchers weren't sure what they were looking for when they studied the UBE3A expression in the postmortem brains of individuals with Angelman syndrome. They found an unknown PCR product in gel electrophoresis, which they later realized came from a naturally occurring antisense RNA expressed only in the paternal chromosome. The Ionis's therapeutic design for Angelman syndrome is simply a reverse engineering of nature's imprinting design: release the imprinting in the paternal chromosome by inhibiting the antisense RNA using ASOs, which will release the repression of paternal UBE3A gene and compensate for the deletion of maternal copy. The design worked great in preclinical animal models. Based on Ionis's recent press release, it seems to be working in humans as well. ir.ionispharma.com/news-rele…
Great paper on the genome-wide associations of copy number variations (CNVs) with seizure disorders. If I have to choose one thing that is most fascinating of all human genetic variations, it is CNV. Let’s talk about CNVs. (a long weekend read) Copy number variations are large structural alterations of the human genome that increase or—often—decrease the gene copies. CNVs frequently fracture large fragments of the human genome, and expectedly, show high penetrance. So, there is no shortage of phenotypes. The major challenge though is to map which gene is causing which phenotype. In the past few days, we have seen stories of GWAS loci that are being hammered by scientists for decades to reveal their secrets. If you were amazed by those stories, wait until you hear about CNVs that are being hammered for more than a century and yet they haven’t spilt even half of their secrets. Let’s zoom into one of the tallest towers in chromosome 15 of this Manhattan plot, which holds one of the most fascinating puzzles—15q11-q13 deletions—that evolution has handed over to human geneticists to solve. Origins of Prader-Willi and Angelman syndromes The earliest record of Prader-Willi syndrome dates back to the 1880s. John Langdon Down (famously known for his discovery of Down syndrome) in his classical text Mental Affections of Childhood and Youth described a case of 14 yr old, short-statured, obese and intellectually disabled girl. But these facts only came to light long after the three Swiss doctors Andrea Prader, Heinrich Willi and Alexis Labhart described in 1956 a case series of nine children with the tetrad of short stature, obesity, intellectual disability and small hands and feet and birthed the name “Prader-Labhart-Willi syndrome”. Over time, the syndrome lost its middle name for some reason and now it is just “Prader-Wili Syndrome”. The earliest record of Angelman Syndrome dates back to 1965 when an English physician described a case series of three children that he likened to “happy puppets” because of their phenotypes—laughing demeanour and jerky gait. Needless to say, it took many decades since the first case reports for genetic technologies to advance to know that these syndromes are caused by deletions in the chromosome 15q11-q13 region. Prader-Willi and Angelman—the poster children of imprinting disorders What makes these syndromes fascinating is not merely their structural alterations but the maternal and paternal biases in the expression of those structural alterations. Angelman occurs due to deletions of the 15q11-q13 region that is expressed only in the maternally inherited segments (Angel - Mother, a mnemonic from med school days that is still alive in my memory) and in Prader-Willi, it’s the other way around. Decoding the evolutionary designs behind imprinting One of the Prader-Willi and Angelman puzzles that scientists have been slowly piecing together for decades is understanding the master design that went into the unique maternal and paternal imprinting of the 15q11-q13 regions. The imprinting design of Angelman is my favourite. Many of the clinical features of Angelman Syndrome are due to the deletion of an extremely critical gene *UBE3A* which codes for a ubiquitin ligase and is the master janitor of our cellular buildings; it keeps our cells tidy by degrading the damaged and discarded proteins. And you can imagine the protein chaos that will unfold when this janitor quits. The earliest clues surfaced in 1998 when scientists were poking around the brains of dead people with Angelman Syndrome. They spotted something unusual in the gel electrophoresis pictures that displayed the UBE3A transcripts amplified using RT-PCR. One band, the expected one, corresponded to spliced UBE3A mRNA. But what is the other one? Scientists realized that it was an unspliced UBE3A transcript that came from the paternal allele (unlike the main UBE3A which, as expected, came from the maternal allele). And interestingly, that transcript was amplified only by the primer that recognized the UBE3A sequence oriented inversely (anti-sense) (nature.com/articles/ng0598-1…). Everything fell into place then. It was a naturally occurring UBE3A anti-sense transcript that evolution has placed in the paternal line to ensure that paternal UBE3A is not expressed in the neurons (btw, UBE3A is imprinted only in neurons). Therapeutic exploitation of an evolutionary design How do you re-express the UBE3A in Angelman patients who lost their only active copy? Reverse engineer the evolutionary design. Silence the UBE3A antisense transcript which will release the imprinting in the paternal chromosome resulting in UBE3A expression. The design works well in mice models. Will it lead to success in human clinical trials? We will know soon in the coming years (ncbi.nlm.nih.gov/pmc/article…). The challenge of mapping genotypes to phenotypes Just a few days ago, we saw how scientists were struggling to identify causal genes at the FTO GWAS locus (teapaw.org/doctorveera/stat…). Imagine a similar scenario, but this time instead of one or two causal genes, we have dozens, each of which has its own set of phenotypes and all massively overlap in patients. Compared to the GWAS locus, dissecting the causalities in a CNV locus is many folds complicated. Scientists use many approaches to map the genes in the CNV regions to their phenotypes. One by studying naturally occurring loss of function and gain of function mutations in individual genes and overlapping their phenotypes with CNV phenotypes. This approach easily exposes the genes that have a typical mirror effect. A beautiful example is the gene MMP23, one of the affected genes in CNV 1p36 (the tallest tower in chr 1 in the Manhattan plot). MMP23 codes for a matrix metalloproteinase and controls tissue and bone remodelling. Loss of MMP23 delays cranial bone fusions resulting in large anterior fontanelles in the affected babies and gain of MMP23 fuses cranial bones too early resulting in craniosynostosis (nature.com/articles/5201302). But not all genes are easy as MMP23 to understand. In fact, MMP23 is the only gene that was confidently mapped to a phenotype in the 1p36 locus. I recently discussed another similar example: mapping the OCA2 in the 15q11-q13 region to skin pigmentation (teapaw.org/doctorveera/stat…). Bottom line (literally) CNVs are some of the best examples to showcase the challenges of genotype to phenotype mapping in human genetics, which takes collective efforts that often span many many decades and hundreds of scientists. Congrats to Dennis Lal and the team for pushing such efforts one step forward in the right direction.
1
11
46
7,707